GSK’s Terrell On ‘Relentless’ Digital Consumption Across the Spectrum
GSK’s first chief digital and technology officer shares with Scrip her views on things digital that could potentially transform the pharmaceutical business, the ex-Walmart executive noting how digital touch points with physicians are improving “in every single geography and every single product.”
You may also be interested in...
Indian firms are getting their act together in areas like cell and gene therapy, with Dr Reddy’s aiming big and readying a facility alongside an alliance with a Chinese firm for a CAR-T therapy. The company is also doubling down in contract development and manufacturing, with an eye on opportunities in biologics.
Big pharma R&D leaders discuss the confluence of technology and biotech driving insights into biology and how industry is doing in terms of identifying patients earlier in disease.
ImmunoACT CEO Dr Rahul Purwar outlines progress made by the firm’s early-stage CAR-T therapy in India, which he believes can be available at a tenth of the price of current on-market treatments or around the cost range for bone marrow transplant. Laurus Labs, which holds about 27% in ImmunoACT, is expected to help shape the firm’s globalization plans.